Charles River Laboratories International (NYSE:CRL) Stock Price Target Raised at Barclays

Charles River Laboratories International (NYSE:CRL) had its target price lifted by Barclays from $330.00 to $375.00 in a research note published on Thursday morning,Benzinga reports. Barclays currently has an overweight rating on the medical research company’s stock.

CRL has been the subject of a number of other research reports. Robert W. Baird lifted their target price on Charles River Laboratories International from $291.00 to $334.00 and gave the stock an “outperform” rating in a report on Friday, September 25th. CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research note on Monday, July 20th. Morgan Stanley raised their price target on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. UBS Group started coverage on shares of Charles River Laboratories International in a research note on Wednesday, September 30th. They issued a “buy” rating and a $357.00 price objective for the company. Finally, Argus set a $330.00 price objective on shares of Charles River Laboratories International in a report on Thursday, September 17th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $308.17.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $312.54 on Thursday. The firm has a market cap of $14.92 billion, a P/E ratio of 343.46, a price-to-earnings-growth ratio of 3.04 and a beta of 1.36. The business’s 50 day moving average is $304.89 and its 200-day moving average is $224.59. The company has a current ratio of 1.41, a quick ratio of 1.04 and a debt-to-equity ratio of 0.76. Charles River Laboratories International has a 1-year low of $146.20 and a 1-year high of $379.63.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.12. The business had revenue of $982.73 million during the quarter, compared to the consensus estimate of $960.36 million. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The firm’s quarterly revenue was down 2.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.43 EPS. Equities research analysts predict that Charles River Laboratories International will post 11.41 earnings per share for the current year.

Insider Activity

In other Charles River Laboratories International news, Director James C. Foster sold 24,042 shares of the stock in a transaction dated Thursday, October 22nd. The shares were sold at an average price of $350.00, for a total transaction of $8,414,700.00. Following the sale, the director directly owned 31,596 shares in the company, valued at $11,058,600. This represents a 43.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total transaction of $163,442.52. Following the sale, the director owned 1,438 shares in the company, valued at $410,175.12. The trade was a 28.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 102,299 shares of company stock worth $31,050,863. 1.30% of the stock is owned by company insiders.

Institutional Trading of Charles River Laboratories International

Several large investors have recently made changes to their positions in the company. Physician Wealth Advisors Inc. boosted its holdings in shares of Charles River Laboratories International by 127.9% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 55 shares in the last quarter. Continuum Advisory LLC acquired a new position in Charles River Laboratories International in the 2nd quarter worth about $30,000. IFP Advisors Inc increased its holdings in Charles River Laboratories International by 182.8% in the 3rd quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock worth $48,000 after purchasing an additional 106 shares in the last quarter. Compass Wealth Management LLC bought a new position in Charles River Laboratories International in the third quarter valued at about $69,000. Finally, Activest Wealth Management raised its position in Charles River Laboratories International by 25.9% in the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock valued at $82,000 after purchasing an additional 57 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Key Stories Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: UBS raised its price target to $387 from $357 and maintained a Buy rating. UBS rating
• Positive Sentiment: Barclays increased its target to $375 from $330 with an Overweight rating, while RBC raised its target to $352 from $322 and kept its Outperform rating. Barclays rating RBC rating
• Positive Sentiment: CRL reported Q3 adjusted earnings of $3.09 per share, above estimates, and revenue of $982.7 million, also ahead of forecasts. Organic growth and margin expansion helped the company raise its 2026 outlook. Q3 earnings and outlook
• Negative Sentiment: Revenue fell 2.2% year over year. The market’s focus on softer sales despite earnings and revenue beats, as well as margin gains, appears to have tempered the positive results. Q3 market reaction
• Negative Sentiment: Zacks Research downgraded CRL from Strong Buy to Hold, adding a more cautious analyst view. Zacks Research rating

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.